ABP 938
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ABP 938, covering 2024-01-05 to 2025-02-14. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD) [Phase 3]